Communiqués Moderna, Inc.

Actions

MRNA

US60770K1079

Produits pharmaceutiques

Temps réel estimé Cboe BZX 20:48:49 14/08/2026			Varia. 5j.	Varia. 1 janv.
63,53 ^USD	-0,19%		+7,42%	+115,53%

11/08	L'épidémie d'Ebola franchit le cap des 2000 morts en RDC	AW
10/08	Rocket Lab progresse porté par l'engouement pour l'espace ; Moderna s'anime grâce à son vaccin contre la grippe \| Les valeurs à suivre	MT

Communiqués

06/08	Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA	AQ
04/08	Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus	AQ
31/07	Moderna: Q2 Earnings Snapshot	AQ
31/07	Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
16/07	Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors	AQ
09/07	Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026	AQ
08/07	Moderna Appoints Michael McDonnell to Board of Directors	AQ
25/06	Moderna Science Day Highlights Expanding Potential of mRNA Platform	AQ
18/06	Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine	AQ
17/06	Moderna to Host Investor Event - Science Day	AQ
16/06	Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028	AQ
09/06	Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome	AQ
02/06	Moderna to Present at Upcoming Conference in June 2026	AQ
01/06	Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus	AQ
12/05	Moderna Recognized by TIME as One of the World's Most Impactful Companies	AQ
06/05	Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010	AQ
04/05	Moderna : Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna : Transcript (MRNA USQ Transcript 2026 05 01 1)	PU
01/05	Moderna : Earnings Presentation (Moderna 1Q26 Earnings Presentation FINAL)	PU
01/05	Moderna: Q1 Earnings Snapshot	AQ
01/05	Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
22/04	Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines)	PU
22/04	Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate	AQ
21/04	Moderna : ESCMID 2026 (mRNA-1010 Phase 3 sequential administration in adults 50+)	PU
21/04	Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting	AQ